Constipation isn’t always just constipation. If you’re dealing with hard stools, infrequent bowel movements, bloating, and abdominal discomfort that improves after you go, you may be experiencing IBS-C (irritable bowel syndrome—constipation predominant). That distinction matters, because IBS-C is not simply a motility problem—it’s a brain–gut disorder, and treating it like routine constipation often leads to frustration for both patients and providers.
IBS-C is defined by recurrent abdominal pain associated with bowel movements, along with a pattern of predominantly hard stools. Using the Rome IV criteria, patients must have abdominal pain at least one day per week, related to defecation or associated with a change in stool frequency or form. In IBS-C specifically, more than 25% of stools are hard (Bristol types 1–2), and less than 25% are loose. What separates IBS-C from chronic constipation is the presence of pain. Patients with simple constipation may feel uncomfortable, but those with IBS-C often describe cramping, pressure, and bloating that fluctuate with bowel activity and improve after a bowel movement.
Diagnosis is primarily clinical and starts with recognizing the pattern of symptoms. Equally important is identifying what IBS is not. Red flag symptoms—such as rectal bleeding, unexplained weight loss, iron deficiency anemia, a family history of colorectal cancer, or new-onset symptoms later in life—should prompt further evaluation before labeling symptoms as IBS. In the absence of these features, testing is usually limited and may include basic labs such as a complete blood count, celiac screening, or thyroid function tests. Colonoscopy is reserved for appropriate indications rather than routine diagnosis.
Treatment of IBS-C requires addressing both bowel function and pain signaling, which is why standard constipation treatments alone often fall short. Fiber is typically the first step, but not all fiber is created equal. Soluble fibers such as psyllium or partially hydrolyzed guar gum (PHGG) are generally better tolerated and more effective, while insoluble fibers like bran can worsen bloating and discomfort. Osmotic laxatives such as polyethylene glycol or magnesium can help improve stool frequency, but they do not reliably address the pain component of IBS.
For patients with persistent symptoms, prescription therapies can be particularly helpful. Medications such as linaclotide, plecanatide, and lubiprostone work by increasing intestinal fluid secretion and improving motility, while also reducing visceral hypersensitivity. These treatments target both stool consistency and the underlying pain pathways, making them more effective than laxatives alone in IBS-C.
Equally important—and often overlooked—is the role of the brain–gut axis. Stress, sleep disruption, and nervous system dysregulation can amplify IBS symptoms. Therapies such as cognitive behavioral therapy, gut-directed hypnotherapy, and stress management techniques are not “adjuncts”—they are core components of treatment for many patients. Dietary strategies also play a role, particularly short-term use of a low FODMAP diet to identify triggers, followed by careful reintroduction to avoid unnecessary long-term restriction.
In some patients, especially those who feel like they “can’t go” despite the urge, pelvic floor dysfunction may be contributing. These patients benefit more from pelvic floor physical therapy than from escalating laxatives, highlighting again the importance of identifying the underlying mechanism rather than simply treating symptoms.
The bottom line is that IBS-C is not just slow bowel movement—it’s a disorder of motility, sensitivity, and brain–gut interaction. Treating the stool alone is not enough. The most effective approach combines targeted dietary strategies, appropriate medications, and attention to the nervous system.
